Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-09-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2015.64.0060PMID 26811524
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

  2015cited by this paper
• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

  2015cited by this paper
• Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

  2014cited by this paper
• Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

  2014cited by this paper
• Management of older or unfit patients with acute myeloid leukemia

  2014cited by this paper
• The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

  2013cited by this paper
• Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

  2013cited by this paper
• A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

  2013cited by this paper
• A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

  2013cited by this paper
• Gemtuzumab ozogamicin: time to resurrect?

  2012cited by this paper
• Treatment of acute myeloid leukemia: are we making progress?

  2012cited by this paper
• The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

  2012cited by this paper
• Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin

  2012cited by this paper
• Survival for older patients with acute myeloid leukemia: a population-based study

  2012cited by this paper
• Azacitidine for the treatment of patients with acute myeloid leukemia

  2012cited by this paper
• Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

  2012cited by this paper
• Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

  2012cited by this paper
• Acute myeloid leukaemia in the elderly: a review

  2011cited by this paper
• Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

  2011cited by this paper
• The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

  2011cited by this paper
• Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

  2010cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19)

  2010influential reference
• A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

  2007cited by this paper
• Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.

  2005cited by this paper
• Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.

  2002cited by this paper
• Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

  2001cited by this paper
• Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

  2001cited by this paper

• Advances in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in the Elderly

  2026cites this paper
• Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism

  2025cites this paper
• Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

  2025cites this paper
• Novel therapies for acute myeloid leukemia. Does age still matter?

  2025cites this paper
• Six events that shaped antibody approvals in oncology

  2025cites this paper
• Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML

  2025influential citation
• Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China

  2025cites this paper
• Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management

  2025cites this paper
• Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody–drug conjugates using FAERS database

  2025cites this paper
• Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies

  2025cites this paper
• Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

  2025cites this paper
• Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study.

  2025cites this paper
• The global epidemiology of acute myeloid leukaemia

  2025cites this paper
• Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population

  2025cites this paper
• Understanding and Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: An Updated Comprehensive Review

  2025cites this paper
• Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions

  2025cites this paper
• Treatment-related adverse events of antibody drug-conjugates in clinical trials

  2025cites this paper
• Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia?

  2025cites this paper
• Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.

  2024cites this paper
• Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis

  2024cites this paper
• Unveiling the Role of New Molecules in Acute Myeloid Leukemia: Insights into Disease Pathogenesis and Therapeutic Potential

  2024cites this paper
• CD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells.

  2024cites this paper
• Navigating Treatment Options and Communication in Relapsed Pediatric AML.

  2024cites this paper
• A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

  2024cites this paper
• Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms—A Systematic Review

  2024influential citation
• Antibody drug conjugates: Design implications for clinicians

  2024cites this paper
• Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada

  2024cites this paper
• Dermatologic Toxicities of Antibody-Drug Conjugates.

  2024cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation.

  2024cites this paper
• A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

  2024cites this paper
• Safety considerations for drugs newly approved for treating acute myeloid leukemia

  2024cites this paper
• Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database

  2024cites this paper
• Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

  2024influential citation
• Pediatric Acute Myeloid Leukemia Post Cytotoxic Therapy—Retrospective Analysis of the Patients Treated in Poland from 2005 to 2022

  2023cites this paper
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

  2023cites this paper
• Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia

  2023cites this paper
• Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future

  2023influential citation
• Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.

  2023cites this paper
• Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies

  2023cites this paper
• Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

  2023cites this paper
• Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer

  2023cites this paper
• Antibody-drug conjugate [ADC] treatment of leukaemia.

  2023cites this paper
• Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

  2023cites this paper
• A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications

  2023cites this paper
• Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment

  2023cites this paper
• FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.

  2023cites this paper
• A comparative safety review of targeted therapies for acute myeloid leukemia

  2023influential citation
• A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system

  2023cites this paper
• Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis

  2023cites this paper
• Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review

  2023cites this paper
• Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG).

  2023cites this paper
• Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature.

  2023cites this paper
• Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.

  2023cites this paper
• Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability

  2023cites this paper
• Drug delivery targets and strategies to address mast cell diseases

  2023cites this paper
• Treatment of Acute Myeloid Leukemia in Older Adults

  2023cites this paper
• Antibody–drug conjugates come of age in oncology

  2023cites this paper
• Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy

  2023cites this paper
• Antibody-drug conjugates: the clinical development in gastric cancer

  2023cites this paper
• Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023

  2023cites this paper
• Non-intensive acute myeloid leukemia therapies for older patients

  2023cites this paper
• Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis

  2023cites this paper
• ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART.

  2023cites this paper
• Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia

  2022cites this paper
• GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance

  2022cites this paper
• Development of therapeutic antibodies for the treatment of diseases

  2022cites this paper
• Immune therapy: a new therapy for acute myeloid leukemia

  2022cites this paper
• Toxicities From Antibody-Drug Conjugates

  2022cites this paper
• A novel immune prognostic model of non-M3 acute myeloid leukemia.

  2022cites this paper
• Advance care planning in older patients with acute myeloid leukemia and myelodysplastic syndromes.

  2022cites this paper
• Therapeutic Advances in Immunotherapies for Hematological Malignancies

  2022cites this paper
• Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

  2022cites this paper
• A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges

  2022cites this paper
• Development of Antibody-Drug Conjugates: Future Perspective towards Solid Tumor Treatment.

  2022cites this paper
• Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy

  2022cites this paper
• 1 Real-world treatment patterns and clinical outcomes in Korean 2 patients with AML ineligible for first-line intensive 3 chemotherapy: A subanalysis of the CURRENT study, a non-4 interventional, retrospective chart review

  2022cites this paper
• Development of a bispecific Antibody–Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia

  2022cites this paper
• Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials

  2022cites this paper
• A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis

  2022influential citation
• Oncology stewardship in acute myeloid leukemia

  2022cites this paper
• How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia

  2022cites this paper
• Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation

  2022cites this paper
• Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making

  2022cites this paper
• Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

  2022cites this paper
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy

  2022cites this paper
• Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

  2022cites this paper
• Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin

  2022cites this paper
• Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study

  2022cites this paper
• Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.

  2022cites this paper
• Emerging new therapeutic antibody derivatives for cancer treatment

  2022cites this paper
• Diagnosis and Treatment of Therapy-related Acute Myeloid Leukemia.

  2022cites this paper
• Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*

  2022cites this paper
• Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

  2022cites this paper
• Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis

  2022cites this paper
• High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

  2022cites this paper
• Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.

  2022cites this paper
• A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types

  2022cites this paper
• Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

  2022cites this paper
• Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

  2022cites this paper